A new device about the size of a business card could allow health care providers to test blood for insulin and other blood proteins, cholesterol, and even signs of viral or bacterial infection all at the same time — with one drop of blood. Preliminary tests of the V-chip, created by scientists at The Methodist Hospital Research Institute and MD Anderson Cancer Center, were published by Nature Communications.
Despite earlier signs that a less-invasive surgery is safer and better than “open” operations to repair potentially lethal abdominal aortic aneurysms, a clinical study led by a Johns Hopkins professor shows survival rates after four years are similar for both procedures.
December 21, 2012 — Nanostim Inc. announced the first successful implants of a leadless pacemaker in a series of 11 patients at Homolka Hospital in Prague, Czech Republic. The leadless pacemakers were implanted by Drs. Petr Neuzil, head of cardiology at Homolka Hospital, and Vivek Reddy, director of electrophysiology at Mount Sinai Hospital in New York.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
December 21, 2012 — Covidien announced the five-year results of the ClosureFast long-term European multicenter study in patients with chronic venous insufficiency (CVI). This study evaluates the five-year outcomes of a minimally invasive endovascular therapy for treatment of CVI.
At RSNA 2012, Hitachi featured its Echelon Oval 1.5T MRI system, which features the widest bore on the market at 74 cm ...
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that the anticoagulant Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
December 20, 2012 — At the 98th annual meeting of the Radiological Society of North America (RSNA), Royal Philips Electronics continued the Imaging 2.0 journey by showcasing several new features for existing image modalities that deliver clinical benefits to customers while simultaneously answering the economic challenges clinicians face worldwide.
Covidien announced that the Solitaire FR Revascularization Device has been approved by Health Canada. The Solitaire FR device is used to restore blood flow to the brain in patients suffering from acute ischemic stroke.
December 20, 2012 — BlipCare has presented the world's first Wi-Fi blood pressure monitor on international crowd funding site Indiegogo.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy stent system and support U.S. Food and Drug Administration (FDA) and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
New streamlined guidelines will help healthcare providers better treat patients with the most severe type of heart attacks, according to an American Heart Association/American College of Cardiology statement.
Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the One Snare Endovascular Snare System.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial, “the highly cited open-label Phase II study [of the CardioFit] by De Ferrari et al. demonstrated for the first time that chronic vagus nerve stimulation is associated with improvements in New York Heart Association (NYHA) class, six min[ute] walk test, left ventricular ejection fraction, and systolic volumes up to 1 year, [setting] the stage for further investigations and clinical trials in this new era of device thearapy.”[1,2]
Hospitalized children who suffer cardiac arrest are nearly three times more likely to survive than they were about a decade ago, and no more likely to suffer brain impairment, according to new research in the American Heart Association journal Circulation: Cardiovascular Quality & Outcomes.
December 19, 2012 — The latest generation of diagnostic tests in development is expected to provide information that will be important to patient outcomes, potentially reducing the time to diagnosis of heart attacks by several hours. The specific performance characteristics of several troponin tests were evaluated in a new study published in Clinical Chemistry.[1]